2 January 2026 in Journal of Cosmetic Dermatology
Background: Polynucleotides (PN) are innovative polymers that improve skin hydration and elasticity, serving as alternatives to traditional dermal fillers. Medical devices based on PN High Purification Technology (PN HPT) represent a new generation of injectable products designed to restore hydration, elasticity, and overall tissue quality. PN HPT is known for its clinical versatility and excellent tolerability. Aims: To assess the real‐world performance and safety of Plinest (40 mg/2 mL of PN HPT in a 2 mL pre‐filled syringe), a CE‐marked class III medical device for skin rejuvenation of the face, neck, and décolleté. Methods: This observational clinical data collection involved 66 adult patients, each of whom could receive treatment in up to three areas (face, neck, décolleté). Patients underwent three sessions of intradermal PN HPT injections. A total of 106 questionnaires were collected: 47 for the face, 33 for the neck, and 26 for the décolleté. Performance was evaluated using the Global Clinical Improvement Scale (GCI‐S) and Global Aesthetic Improvement Scale (GAIS). Safety was monitored through spontaneous adverse event (AE) reporting. Results: Clinician‐reported outcomes showed visible improvement in 100% of facial treatments, with 53.5% rated as “marked” or “excellent.” In the neck and décolleté areas, moderate to significant improvements were observed in over 93% and 88% of cases, respectively. Patient satisfaction ranged from 97% to 100%. No serious AEs occurred. Conclusions: PN HPT demonstrated a favorable tolerability and performance profile in real‐life aesthetic practice, supporting its role in improving skin quality and reducing signs of aging.
1 May 2026 in Clinical, Cosmetic and Investigational Dermatology
Introduction and Purpose: Anatomic factors and age‑related changes in the midface, along with sun exposure, prolonged television viewing, anemia, and hormonal derangements, contribute to the development of periorbital hyperpigmentation, also known as dark circles. Intradermally injected PN HPT (Polynucleotides High Purification Technology) from trout gonads has an immediate volume-enhancing effect and a longer-term indirect restructuring action on dermal and subdermal tissues. Methods: Open-label multinational observational cohort of 61 real-life multinational subjects of both genders and unskewed age distribution (mean 41.5 ± 10.5 years, range 20 to 67), with subjectively disturbing dark circles across all Huang subtypes. PN HPT hydrogel (7.5 mg/mL) in phosphate buffer was administered with needle or cannula at baseline (T0), after two to three weeks (second injection, T1), and two to three weeks after T1 (third injection, T2); usually 1 mL on the right periorbicular area and 1 mL on the left (lower doses allowed at the specialist’s discretion). Post-treatment follow-up visits: Snapshot photographs were taken at 1 month (T3) and three months after the final T2 injection (T4) and digitally analyzed for color, pigmentation, and outcomes compared with T0 (primary endpoint). Every participating specialist and every treated subject also assessed hyperpigmentation and skin quality categories with GAIS-like scoring scales. Results: Regarding the primary endpoint, the overall picture showed a generalized, highly significant shift toward less severe periorbital hyperpigmentation (p < 0.001), especially among needle-treated subjects with the structural subtype. The progressive improvements at T3 and T4 in the evaluated perceptual skin quality categories were also remarkable for both participating specialists and treated subjects. Conclusion: The double-edged rationale of low-concentration PN HPT — immediate correction of hollows and tissue loss, and longer-term restructuring of periorbital connective tissues — may be a sound option for improving the appearance of dark circles and the lives of subjects with this aesthetic nuisance.